Veterinary Medicines

Pergosafe 2 mg film-coated tablets for horses

Authorised
  • Pergolide mesilate
Download as PDF

Product identification

Medicine name:
Pergosafe 2 mg film-coated tablets for horses
Pergosafe, 2mg, Potahovaná tableta
Active substance:
  • Pergolide mesilate
Target species:
  • Horse
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Pergolide mesilate
    2.62
    milligram(s)
    /
    1.00
    Piece
Pharmaceutical form:
  • Film-coated tablet
Withdrawal period by route of administration:
  • Oral use
    • Horse
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QN04BC02
Legal status of supply:
This information is not available for this product.
Authorisation status:
  • Valid
Authorised in:
  • Czechia
Package description:
  • PVC-PE-PVDC-aluminium blisters, containing 10 tablets each, in a carton box (60 tablets)
  • PVC-PE-PVDC-aluminium blisters, containing 10 tablets each, in a carton box (30 tablets)
  • PVC-PE-PVDC-aluminium blisters, containing 10 tablets each, in a carton box (90 tablets)
  • OPA-aluminium-PVC-aluminium blisters, containing 10 tablets each, in a carton box (160 tablets)
  • OPA-aluminium-PVC-aluminium blisters, containing 10 tablets each, in a carton box (120 tablets)
  • OPA-aluminium-PVC-aluminium blisters, containing 10 tablets each, in a carton box (100 tablets)
  • OPA-aluminium-PVC-aluminium blisters, containing 10 tablets each, in a carton box (10 tablets)
  • PVC-PE-PVDC-aluminium blisters, containing 10 tablets each, in a carton box (120 tablets)
  • PVC-PE-PVDC-aluminium blisters, containing 10 tablets each, in a carton box (240 tablets)
  • PVC-PE-PVDC-aluminium blisters, containing 10 tablets each, in a carton box (160 tablets)
  • OPA-aluminium-PVC-aluminium blisters, containing 10 tablets each, in a carton box (240 tablets)
  • PVC-PE-PVDC-aluminium blisters, containing 10 tablets each, in a carton box (100 tablets)
  • PVC-PE-PVDC-aluminium blisters, containing 10 tablets each, in a carton box (10 tablets)
  • OPA-aluminium-PVC-aluminium blisters, containing 10 tablets each, in a carton box (90 tablets)
  • OPA-aluminium-PVC-aluminium blisters, containing 10 tablets each, in a carton box (60 tablets)
  • OPA-aluminium-PVC-aluminium blisters, containing 10 tablets each, in a carton box (30 tablets)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Hybrid application (Article 13(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Alfasan Nederland B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Lelypharma B.V.
  • Alfasan Nederland B.V.
Responsible authority:
  • Institute For State Control Of Veterinary Biologicals And Medicines
Authorisation number:
  • 96/037/21-C
Date of authorisation status change:
Reference member state:
  • Netherlands
Procedure number:
  • NL/V/0357/003
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Combined File of all Documents

English (PDF)
Published on: 28/03/2023
Download

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Czech (PDF)
Published on: 24/05/2023
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Czech (PDF)
Published on: 9/05/2024
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Czech (PDF)
Published on: 24/05/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."